Novo Nordisk's Oral Dominance: Wegovy Pill Commands 89% of New Oral Weight-Loss Market, Offsetting Total Share Pressures
As Novo Nordisk (NYSE: NVO) prepares for its upcoming Q2 2026 earnings report, its commercial strategy in the oral weight-loss segment is delivering stellar results. The company's oral weight-loss pill, oral Wegovy (semaglutide), has established a commanding lead in the newly formed oral GLP-1 market, capturing 89% of the oral weight-loss pill prescription volume and successfully fending off Eli Lilly's rival pill, Foundayo (orforglipron).
Oral Wegovy Dominates the Script Wars
According to IQVIA prescription data compiled for the week ending July 17, 2026, oral Wegovy is maintaining a high-volume trajectory:
- Weekly Scripts: Oral Wegovy recorded 147,500 prescriptions for the week, down slightly from its peak of over 161,000, but representing a highly mature launch.
- Wegovy Franchise Contribution: The oral tablet formulation now consistently accounts for about one-third of all Wegovy prescriptions (which total 448,500 scripts across both injectable and oral formats).
- Comparison to Lilly's Foundayo: In the same week, Eli Lilly's Foundayo registered 24,303 scripts. In its 13th week post-launch, Foundayo logged just 19,550 scripts, whereas oral Wegovy had surpassed 105,000 weekly scripts by its 13th week.
Key Pillars of Novo's Oral Success
Industry analysts and physicians attribute Novo's overwhelming oral lead to several structural advantages:
- First-Mover Advantage: Oral Wegovy launched in January 2026, securing a crucial three-month head start before Foundayo entered the market in April 2026.
- Immediate Brand Recognition: Novo Nordisk has successfully leveraged the household-name familiarity of the "Wegovy" brand. Patients and doctors were already highly familiar with Wegovy, whereas Eli Lilly has had to build brand awareness for "Foundayo" from scratch.
- Efficacy Superiority: Clinical trial data has shown that oral Wegovy achieved an average 16.6% body weight reduction after more than a year of treatment, compared to 12.4% for Foundayo.
- Day-One Formulary Coverage: Oral Wegovy secured comprehensive pharmacy benefit manager (PBM) coverage from its first week on the market. In contrast, CVS Caremark (one of the big three PBMs) delayed coverage for Foundayo until June 1, 2026, creating a major early-stage bottleneck for Lilly.
The Broader Obesity Battleground
While Novo Nordisk is the undisputed king of the oral weight-loss market, it continues to face intense competitive pressure from Eli Lilly in the broader injectables space. Eli Lilly maintains a 59.5% share of the total U.S. obesity market, with weekly prescriptions for Zepbound (~660,000) comfortably outpacing total Wegovy scripts (~448,500).
Furthermore, the oral GLP-1 market remains highly dynamic. While Novo leads today, the long-term sustainability of oral Wegovy's growth will depend on patient retention rates—a metric that analysts will closely scrutinize during Novo's Q2 earnings call on August 5, 2026.